0001104659-24-060006.txt : 20240510 0001104659-24-060006.hdr.sgml : 20240510 20240510172520 ACCESSION NUMBER: 0001104659-24-060006 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240508 FILED AS OF DATE: 20240510 DATE AS OF CHANGE: 20240510 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Mika Yuval CENTRAL INDEX KEY: 0001949285 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39421 FILM NUMBER: 24936120 MAIL ADDRESS: STREET 1: 150 UNION SQUARE DRIVE CITY: NEW HOPE STATE: PA ZIP: 18938 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Orchestra BioMed Holdings, Inc. CENTRAL INDEX KEY: 0001814114 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 150 UNION SQUARE DRIVE CITY: NEW HOPE STATE: PA ZIP: 18938 BUSINESS PHONE: 646-343-9298 MAIL ADDRESS: STREET 1: 150 UNION SQUARE DRIVE CITY: NEW HOPE STATE: PA ZIP: 18938 FORMER COMPANY: FORMER CONFORMED NAME: Health Sciences Acquisitions Corp 2 DATE OF NAME CHANGE: 20200603 4 1 tm2414108-7_4seq1.xml OWNERSHIP DOCUMENT X0508 4 2024-05-08 0 0001814114 Orchestra BioMed Holdings, Inc. OBIO 0001949285 Mika Yuval C/O ORCHESTRA BIOMED HOLDINGS, INC. 150 UNION SQUARE DRIVE NEW HOPE PA 18938 0 1 0 0 See Remarks 0 Common Stock, par value $0.0001 per share ("Common Stock") 2024-05-08 4 A 0 69333 0 A 158905 D Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest as follows: (i) 10,400 RSUs will vest on May 18, 2025, and (ii) the remaining 58,933 RSUs will vest in equal installments on August 18, 2025, November 18, 2025, December 18, 2025, May 18, 2026, August 18, 2026, November 18, 2026, March 25, 2027, May 18, 2027, August 18, 2027, November 18, 2027, March 25, 2028 and May 18, 2028, subject to the Reporting Person's continuous service through such dates. General Manager and Chief Technology Officer, Bioelectronic Therapies /s/ Matthew R. Schob, Attorney-in-Fact 2024-05-10